BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, Cavallone D, Bonino F. Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology 2010;139:483-90. [DOI: 10.1053/j.gastro.2010.04.052] [Cited by in Crossref: 258] [Cited by in F6Publishing: 234] [Article Influence: 23.5] [Reference Citation Analysis]
Number Citing Articles
1 Su TH, Liu CJ, Yang HC, Jeng YM, Cheng HR, Liu CH, Tseng TC, Ling TY, Chen PJ, Chen DS. Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. J Gastroenterol. 2014;49:356-362. [PMID: 23736797 DOI: 10.1007/s00535-013-0840-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
2 Alghamdi A, Aref N, El-Hazmi M, Al-Hamoudi W, Alswat K, Helmy A, Sanai FM, Abdo AA. Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol 2013;19:252-7. [PMID: 24195978 DOI: 10.4103/1319-3767.121035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
3 Hsu Y, Mo L, Chang C, Wu M, Yang T, Kao J, Chen C, Tseng C, Tai C, Lin C, Wu C, Lin J. Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy: Clinical hepatitis B flare off entecavir. Journal of Gastroenterology and Hepatology 2017;32:1512-9. [DOI: 10.1111/jgh.13728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014;29:1028-1034. [PMID: 24325451 DOI: 10.1111/jgh.12476] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
5 Coffin CS, Osiowy C, Myers RP, Gill MJ. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. J Clin Virol 2013;57:103-8. [PMID: 23465393 DOI: 10.1016/j.jcv.2013.02.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
6 Wang H, Ru GQ, Yan R, Zhou Y, Wang MS, Cheng MJ. Histologic Disease in Chinese Chronic Hepatitis B Patients With Low Viral Loads and Persistently Normal Alanine Aminotransferase Levels. J Clin Gastroenterol 2016;50:790-6. [PMID: 27182648 DOI: 10.1097/MCG.0000000000000544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
7 Zhang P, Du H, Tong G, Li X, Sun X, Chi X, Xing Y, Zhou Z, Li Q, Chen B, Wang H, Wang L, Jin H, Mao D, Wang X, Wu Q, Li F, Hu X, Lu B, Yang Z, Zhang M, Shi W, He Q, Li Y, Jiang K, Xue J, Li X, Jiang J, Lu W, Tian G, Hu Z, Guo J, Li C, Deng X, Luo X, Li F, Zhang X, Zheng Y, Zhao G, Wang L, Wu J, Guo H, Mi Y, Gong Z, Wang C, Jiang F, Guo P, Yang X, Shi W, Yang H, Zhou Y, Sun N, Jiao Y, Gao Y, Zhou D, Ye Y. Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: A multicentre perspective in China. J Viral Hepat 2018;25:1017-25. [DOI: 10.1111/jvh.12903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
8 Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat. 2012;19:138-146. [PMID: 22239503 DOI: 10.1111/j.1365-2893.2011.01450.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol. 2013;28:1842-1848. [PMID: 23829381 DOI: 10.1111/jgh.12327] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
10 Thibault V, Servant-delmas A, Ly TD, Roque-afonso A, Laperche S. Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples. Journal of Clinical Virology 2017;89:14-21. [DOI: 10.1016/j.jcv.2017.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Chuaypen N, Payungporn S, Poovorawan K, Chotiyaputta W, Piratvisuth T, Tangkijvanich P. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Virus Genes 2019;55:610-8. [PMID: 31359359 DOI: 10.1007/s11262-019-01689-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. Journal of Hepatology 2019;70:615-25. [DOI: 10.1016/j.jhep.2018.11.030] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 42.0] [Reference Citation Analysis]
13 Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol. 2011;55:61-68. [PMID: 21145875 DOI: 10.1016/j.jhep.2010.10.027] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
14 Jang JW. Growing attention to an old marker, hepatitis B surface antigen, in the natural history of chronic hepatitis B. Korean J Hepatol 2010;16:342. [DOI: 10.3350/kjhep.2010.16.3.342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Wijaya RS, Read SA, Schibeci S, Han S, Azardaryany MK, van der Poorten D, Lin R, Yuen L, Lam V, Douglas MW, George J, Ahlenstiel G. Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. Liver Int 2021;41:969-81. [PMID: 33411395 DOI: 10.1111/liv.14784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Amini A, Varsaneux O, Kelly H, Tang W, Chen W, Boeras DI, Falconer J, Tucker JD, Chou R, Ishizaki A, Easterbrook P, Peeling RW. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis 2017;17:698. [PMID: 29143619 DOI: 10.1186/s12879-017-2772-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
17 Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014;4:a024935. [PMID: 25359547 DOI: 10.1101/cshperspect.a024935] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
18 Locarnini S, Bowden S. Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology. 2012;56:411-414. [PMID: 22454331 DOI: 10.1002/hep.25732] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
19 Barone M, Iannone A, Leo AD. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy. World J Gastroenterol 2014; 20(26): 8722-8725 [PMID: 25024631 DOI: 10.3748/wjg.v20.i26.8722] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
20 Tseng TC, Kao JH, Chen DS. Peginterferon α in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2014;14:995-1006. [PMID: 24738850 DOI: 10.1517/14712598.2014.907784] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
21 Ungtrakul T, Sriprayoon T, Kusuman P, Chunnuan P, Soonklang K, Sornsamdang G, Auewarakul CU, Tanwandee T. Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Medicine (Baltimore) 2017;96:e6554. [PMID: 28353619 DOI: 10.1097/MD.0000000000006554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
22 Taghiabadi M, Hosseini SY, Gorzin AA, Taghavi SA, Monavari SHR, Sarvari J. Comparison of pre-S1/S2 variations of hepatitis B virus between asymptomatic carriers and cirrhotic/hepatocellular carcinoma-affected individuals. Clin Exp Hepatol 2019;5:161-8. [PMID: 31501793 DOI: 10.5114/ceh.2019.84781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer K. Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection. Aliment Pharmacol Ther 2018;47:1523-35. [DOI: 10.1111/apt.14636] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
24 Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol 2014; 20(24): 7644-7652 [PMID: 24976702 DOI: 10.3748/wjg.v20.i24.7644] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
25 Tseng TC, Kao JH. Elimination of Hepatitis B: Is It a Mission Possible? BMC Med 2017;15:53. [PMID: 28292309 DOI: 10.1186/s12916-017-0820-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
26 Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, Kronenberger B, Piiper A. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat. 2012;19:e58-e65. [PMID: 22239527 DOI: 10.1111/j.1365-2893.2011.01536.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 8.5] [Reference Citation Analysis]
27 Seto WK, Wong DK, Fung J, Hung IF, Yuen JC, Tong T, Lai CL, Yuen MF. Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Hepatol Int 2012;7:119-26. [PMID: 24466363 DOI: 10.1007/s12072-012-9373-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
28 Tseng T, Liu C, Hsu C, Hong C, Su T, Yang W, Chen C, Yang H, Huang Y, Fang-tzu Kuo S, Liu C, Chen P, Chen D, Kao J. High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Gastroenterology 2019;157:1518-1529.e3. [DOI: 10.1053/j.gastro.2019.08.028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
29 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
30 Han ZG, Qie ZH, Qiao WZ. HBsAg spontaneous seroclearance in a cohort of HBeAg-seronegative patients with chronic hepatitis B virus infection. J Med Virol. 2016;88:79-85. [PMID: 26111498 DOI: 10.1002/jmv.24311] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
31 Tseng T, Liu C, Yang W, Chen C, Yang H, Su T, Wang C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters: HBsAg levels predict viral reactivation. J Gastroenterol Hepatol 2014;29:1242-9. [DOI: 10.1111/jgh.12502] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
32 Ruan P, Xu SY, Zhou BP, Huang J, Gong ZJ. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study. J Int Med Res 2013;41:1732-9. [PMID: 23908397 DOI: 10.1177/0300060513487643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
33 Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, Gitto S, Bontadini A, Bernardi M, Grossi P, Costa AN, Pinna AD, Brander C, Andreone P. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol. 2012;56:579-585. [PMID: 22027583 DOI: 10.1016/j.jhep.2011.09.016] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
34 Carey I, Bruce M, Horner M, Zen Y, D'Antiga L, Bansal S, Vergani D, Mieli-Vergani G. HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy. J Viral Hepat 2015;22:441-52. [PMID: 25278170 DOI: 10.1111/jvh.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, Janssen HL. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. Journal of Clinical Virology 2011;51:175-8. [DOI: 10.1016/j.jcv.2011.04.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
36 Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34 Suppl 1:97-107. [PMID: 24373085 DOI: 10.1111/liv.12403] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 9.7] [Reference Citation Analysis]
37 Park Y, Hong DJ, Shin S, Cho Y, Kim H. Performance Evaluation of New Automated Hepatitis B Viral Markers in the Clinical Laboratory: Two Quantitative Hepatitis B Surface Antigen Assays and an HBV Core–Related Antigen Assay. Am J Clin Pathol 2012;137:770-7. [DOI: 10.1309/ajcp8qdn7nauxjfj] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, Boo N, Dhotte P, Varsat B, Muller G. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol. 2013;58:473-478. [PMID: 23183527 DOI: 10.1016/j.jhep.2012.11.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
39 Invernizzi F, Viganò M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 Suppl 1:100-104. [PMID: 26725905 DOI: 10.1111/liv.13006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
40 Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7:148-155. [PMID: 25057295 DOI: 10.1177/1756283x14524614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
41 Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57:196-202. [PMID: 22450396 DOI: 10.1016/j.jhep.2011.11.030] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 12.1] [Reference Citation Analysis]
42 Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016;5:pii: F1000. [PMID: 27635243 DOI: 10.12688/f1000research.8983.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
43 McMahon BJ, Bulkow L, Simons B, Zhang Y, Negus S, Homan C, Spradling P, Teshale E, Lau D, Snowball M. Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen-Negative Persons With Hepatitis B. Clin Gastroenterol Hepatol. 2014;12:701-706.e3. [PMID: 24035774 DOI: 10.1016/j.cgh.2013.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
44 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
45 Yang HC, Shih YF, Liu CJ. Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. J Infect Dis 2017;216:S757-64. [PMID: 29156050 DOI: 10.1093/infdis/jix461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, Pittaluga F, Coppola N, Wedemeyer H, Zachou K, Marrone A, Fasano M, Lotti G, Andreone P, Iacobellis A, Andriulli A, Rizzetto M. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Ther. 2016;44:620-628. [PMID: 27443972 DOI: 10.1111/apt.13734] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
47 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
48 Ma G, Lou B, Lv F, Zhao D, Chen H, Ye X, Chen Y. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: "Loss of HBsAg" maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264-9. [PMID: 31730814 DOI: 10.1016/j.cca.2019.10.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Nasser M, Zayed N, Gamal Eldeen H, Abdo M, Kabara Y, Elserafy M. Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus. Arab J Gastroenterol 2021;22:151-7. [PMID: 34090829 DOI: 10.1016/j.ajg.2021.05.003] [Reference Citation Analysis]
50 Besharat S, Katoonizadeh A, Moossavi S, Darvishi Z, Roshandel G, Poustchi H, Mohamadkhani A. The possible impact of sortilin in reducing HBsAg expression in chronic hepatitis B. J Med Virol 2016;88:647-52. [PMID: 26331452 DOI: 10.1002/jmv.24367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
51 Yeon JE. [Clinical significance of hepatitis B surface antigen quantification in chronic hepatitis B]. Korean J Gastroenterol 2014;63:335-40. [PMID: 24953609 DOI: 10.4166/kjg.2014.63.6.335] [Reference Citation Analysis]
52 Yang HC, Kao JH. Looking into the crystal ball: biomarkers for outcomes of HBV infection. Hepatol Int 2016;10:99-101. [PMID: 26732689 DOI: 10.1007/s12072-015-9698-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
53 Yuan H, Lee WM. Update of chronic hepatitis B. Curr Opin Gastroenterol. 2011;27:217-223. [PMID: 21423004 DOI: 10.1097/MOG.0b013e32834595b5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
54 Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology. 2012;56:812-819. [PMID: 22422518 DOI: 10.1002/hep.25718] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 7.4] [Reference Citation Analysis]
55 Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat 2015;22:427-32. [DOI: 10.1111/jvh.12309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
56 Atay A, Seven G, Yalcin K, Pasa S, Degertekin H. Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection. J Int Med Res 2012;40:1891-6. [DOI: 10.1177/030006051204000529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Mixson-Hayden T, Purdy MA, Ganova-Raeva L, McGovern D, Forbi JC, Kamili S. Evaluation of performance characteristics of hepatitis B e antigen serologic assays. J Clin Virol 2018;109:22-8. [PMID: 30388663 DOI: 10.1016/j.jcv.2018.10.005] [Reference Citation Analysis]
58 Tseng T, Liu C, Su T, Wang C, Chen C, Chen P, Chen D, Kao J. Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. Gastroenterology 2011;141:517-525.e2. [DOI: 10.1053/j.gastro.2011.04.046] [Cited by in Crossref: 138] [Cited by in F6Publishing: 142] [Article Influence: 13.8] [Reference Citation Analysis]
59 Viganò M, Lampertico P. Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol. 2012;18:81-86. [PMID: 22421711 DOI: 10.4103/1319-3767.93805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
60 Yang SC, Lu SN, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatol Int. 2013;7:489-499. [PMID: 26201781 DOI: 10.1007/s12072-012-9382-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
61 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
62 Post G, Howell J, Sow A, Ndow G, Chemin I, Lo G, Cessay A, Cohen D, Njie R, Toure S, Diop M, Sombie R, Nana J, Leroy V, Lacombe K, Bojang L, Tacke F, Toure-Kane C, Ka M, Mendy M, Mboup S, Thursz M, Shimakawa Y, Ingiliz P, Lemoine M. Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. J Viral Hepat 2021;28:1003-10. [PMID: 33749097 DOI: 10.1111/jvh.13499] [Reference Citation Analysis]
63 Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Huang TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN. Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. J Formos Med Assoc 2021;120:847-53. [PMID: 32896456 DOI: 10.1016/j.jfma.2020.08.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. Journal of Hepatology 2017;66:897-909. [DOI: 10.1016/j.jhep.2016.12.024] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 19.0] [Reference Citation Analysis]
65 Zhang ZQ, Lu W, Wang YB, Weng QC, Zhang ZY, Yang ZQ, Feng YL. Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients. J Virol Methods. 2016;235:92-98. [PMID: 27230224 DOI: 10.1016/j.jviromet.2016.05.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
66 Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol. 2017;112:1564-1574. [PMID: 28853728 DOI: 10.1038/ajg.2017.254] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
67 Seto WK, Wong DK, Fung J, Ip PP, Yuen JC, Hung IF, Lai CL, Yuen MF. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7:e43087. [PMID: 22916211 DOI: 10.1371/journal.pone.0043087] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
68 Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, Cornberg M, Manns MP, Wedemeyer H. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. Journal of Clinical Virology 2011;50:292-6. [DOI: 10.1016/j.jcv.2010.12.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
69 Leroy V, Chevaliez S, Decraecker M, Roulot D, Nana J, Asselah T, Causse X, Durantel D, Thibaut V, Ganne-Carrié N, Bureau C, de Lédinghen V, Bourlière M. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS B VIRUS. Clin Res Hepatol Gastroenterol 2021;:101773. [PMID: 34332134 DOI: 10.1016/j.clinre.2021.101773] [Reference Citation Analysis]
70 Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus AD, Pas SD, Janssen HL, Boonstra A. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology. 2015;62:87-100. [PMID: 25808668 DOI: 10.1002/hep.27805] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 13.2] [Reference Citation Analysis]
71 Bessone F. Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B. Liver Int. 2014;34:991-1000. [PMID: 25098191 DOI: 10.1111/liv.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
72 Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirotchanakul S, Phisalprapa P, Tanwandee T, Wursthorn K, Brunetto MR, Wedemeyer H. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol. 2011;18:1943-1950. [PMID: 21880853 DOI: 10.1128/cvi.05122-11] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
73 Tuaillon E, Mondain AM, Nagot N, Ottomani L, Kania D, Nogue E, Rubbo PA, Pageaux GP, Van de Perre P, Ducos J. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One 2012;7:e32143. [PMID: 22403628 DOI: 10.1371/journal.pone.0032143] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
74 Yang H, Kao J. Revisiting the Natural History of Chronic HBV Infection. Curr Hepatology Rep 2016;15:141-9. [DOI: 10.1007/s11901-016-0304-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
75 Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013;17:399-412. [PMID: 23905812 DOI: 10.1016/j.cld.2013.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
76 Praneenararat S, Chamroonkul N, Sripongpun P, Kanngurn S, Jarumanokul R, Piratvisuth T. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. BMC Gastroenterol. 2014;14:218. [PMID: 25523185 DOI: 10.1186/s12876-014-0218-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
77 Dimzova M, Kondova-Topuzovska I, Bosilkovski M, Ivanovski L, Milenkovic Z, Semenakova-Cvetkovska V, Orovcanec N. Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2018;6:1052-8. [PMID: 29983800 DOI: 10.3889/oamjms.2018.122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398-411. [PMID: 27575311 DOI: 10.1016/j.jhep.2016.08.009] [Cited by in Crossref: 157] [Cited by in F6Publishing: 150] [Article Influence: 31.4] [Reference Citation Analysis]
79 Cavallone D, Moriconi F, Colombatto P, Oliveri F, Bonino F, Brunetto MR. Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. Journal of Virological Methods 2013;189:110-7. [DOI: 10.1016/j.jviromet.2013.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
80 Goyal SK, Jain AK, Dixit VK, Shukla SK, Kumar M, Ghosh J, Ranjan A, Gupta N, Tripathi M. HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. J Clin Exp Hepatol 2015;5:213-20. [PMID: 26628839 DOI: 10.1016/j.jceh.2015.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
81 Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408-414. [PMID: 21742839 DOI: 10.1093/infdis/jir283] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 7.8] [Reference Citation Analysis]
82 Liu WR, Tian MX, Jin L, Yang LX, Ding ZB, Shen YH, Peng YF, Zhou J, Qiu SJ, Dai Z. High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads. Ann Surg Oncol. 2015;22:843-850. [PMID: 25269529 DOI: 10.1245/s10434-014-4043-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
83 Loggi E, Conti F, Cucchetti A, Ercolani G, Pinna AD, Andreone P. Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature. World J Gastroenterol 2016; 22(35): 8010-8016 [PMID: 27672295 DOI: 10.3748/wjg.v22.i35.8010] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
84 Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64:667-672. [PMID: 24833635 DOI: 10.1136/gutjnl-2014-307237] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 18.1] [Reference Citation Analysis]
85 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014; 20(34): 12045-12055 [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, Lindh M. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int 2014;34:e238-45. [DOI: 10.1111/liv.12345] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
87 Li MH, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Li ZZ, Hua WH, Song SJ, Xie Y. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chin Med J (Engl) 2017;130:559-65. [PMID: 28229987 DOI: 10.4103/0366-6999.200554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
88 Hadziyannis S, Liaw YF. Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B. Gut. 2015;64:1005-1006. [PMID: 25410164 DOI: 10.1136/gutjnl-2014-308677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
89 Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol. 2016;50:691-703. [PMID: 27623512 DOI: 10.1097/mcg.0000000000000647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, Lu SN. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. PLoS One 2016;11:e0166543. [PMID: 27935953 DOI: 10.1371/journal.pone.0166543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Suk-Fong Lok A. Hepatitis B: 50 years after the discovery of Australia antigen. J Viral Hepat. 2015;Aug 17; Epub ahead of print. [PMID: 26280668 DOI: 10.1111/jvh.12444] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
92 Zhang YM, Yang YD, Jia HY, Zeng LY, Yu W, Zhou N, Li LJ. HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions. World J Gastroenterol 2014; 20(15): 4407-4413 [PMID: 24764680 DOI: 10.3748/wjg.v20.i15.4407] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
93 Downs LO, Smith DA, Lumley SF, Patel M, McNaughton AL, Mokaya J, Ansari MA, Salih H, Várnai KA, Freeman O, Cripps S, Phillips J, Collier J, Woods K, Channon K, Davies J, Barnes E, Jeffery K, Matthews PC. Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. mBio 2019;10:e00699-19. [PMID: 31239374 DOI: 10.1128/mBio.00699-19] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
94 Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014;86:131-138. [PMID: 24123090 DOI: 10.1002/jmv.23790] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
95 O'Neil CR, Congly SE, Rose MS, Lee SS, Borman MA, Charlton CL, Osiowy C, Swain MG, Burak KW, Coffin CS. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. Ann Hepatol 2018;17:232-41. [PMID: 31097238 DOI: 10.5604/01.3001.0010.8640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Broquetas T, Garcia-Retortillo M, Hernandez JJ, Puigvehí M, Cañete N, Coll S, Cabrero B, Giménez MD, Solà R, Carrión JA. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. PLoS One 2017;12:e0188303. [PMID: 29190670 DOI: 10.1371/journal.pone.0188303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
97 Chan HL, Thompson A, Martinot-peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao J, Jia J, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology 2011;55:1121-31. [DOI: 10.1016/j.jhep.2011.06.006] [Cited by in Crossref: 206] [Cited by in F6Publishing: 198] [Article Influence: 20.6] [Reference Citation Analysis]
98 Liaw Y. Natural History of Chronic Hepatitis B Virus Infection. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 143-53. [DOI: 10.1002/9781118637272.ch10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Parfieniuk-Kowerda A, Jaroszewicz J, Flisiak R. Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection. Clin Exp Hepatol 2015;1:35-8. [PMID: 28856253 DOI: 10.5114/ceh.2015.51805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
100 Sali S, Sharafi H, Alavian SH, Alavian SM, Etesam F, Salimi S, Merza MA, Keshvari M. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state? Diagn Microbiol Infect Dis 2015;82:114-9. [PMID: 25863529 DOI: 10.1016/j.diagmicrobio.2015.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
101 Magalhães MJ, Pedroto I. Hepatitis B Virus Inactive Carriers: Which Follow-up Strategy? GE Port J Gastroenterol 2015;22:47-51. [PMID: 28868373 DOI: 10.1016/j.jpge.2015.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
102 Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:10-17. [PMID: 23094699 DOI: 10.1111/jgh.12010] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
103 Brunetto MR, Cavallone D, Oliveri F, Moriconi F, Colombatto P, Coco B, Ciccorossi P, Rastelli C, Romagnoli V, Cherubini B, Teilum MW, Blondal T, Bonino F. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS One. 2014;9:e110782. [PMID: 25350115 DOI: 10.1371/journal.pone.0110782] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
104 Wiegand S, Jaroszewicz J, Potthoff A, Höner zu Siederdissen C, Maasoumy B, Deterding K, Manns M, Wedemeyer H, Cornberg M. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clinical Microbiology and Infection 2015;21:710.e1-9. [DOI: 10.1016/j.cmi.2015.03.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
105 Jaroszewicz J, Reiberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, Payer BA, Stoll M, Manns MP, Schmidt RE, Flisiak R, Wedemeyer H, Peck-Radosavljevic M, Rockstroh J, Cornberg M. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS One 2012;7:e43143. [PMID: 22905219 DOI: 10.1371/journal.pone.0043143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
106 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
107 Liaw Y. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review. Hepatology 2011;54:E1-9. [DOI: 10.1002/hep.24473] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
108 Seth AK. HBsAg Quantification in Clinical Practice. J Clin Exp Hepatol 2012;2:75-80. [PMID: 25755408 DOI: 10.1016/S0973-6883(12)60084-X] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
109 Novellino L, Rossi RL, Bonino F, Cavallone D, Abrignani S, Pagani M, Brunetto MR. Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLoS One. 2012;7:e31952. [PMID: 22470417 DOI: 10.1371/journal.pone.0031952] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
110 Martinot-peignoux M, Lapalus M, Laouénan C, Lada O, Netto-cardoso ACF, Boyer N, Ripault MP, Carvalho-filho R, Asselah T, Marcellin P. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. Journal of Clinical Virology 2013;58:401-7. [DOI: 10.1016/j.jcv.2013.08.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
111 Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B: HBsAg revisited. Liver International 2011;31:122-8. [DOI: 10.1111/j.1478-3231.2010.02390.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
112 Mukherjee R, Reddy PB, Arava J, Rao P, Mitnala S, Gupta R, Reddy D. Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection. Hepat Med. 2010;2:157-162. [PMID: 24367213 DOI: 10.2147/hmer.s13796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Berg T, Petersen J; FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B] study authors. Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients". J Hepatol 2018;68:1104-5. [PMID: 29409742 DOI: 10.1016/j.jhep.2018.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virol Sin 2021;36:311-20. [PMID: 32975731 DOI: 10.1007/s12250-020-00290-7] [Reference Citation Analysis]
115 Kim SE. Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B. Korean J Intern Med 2017;32:631-3. [PMID: 28704912 DOI: 10.3904/kjim.2017.209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Moussa S, Brah S, Parola P, Gerolami R, Gamerre M, Boubli L, Ruiz JM, Ravaux I, Mokhtari S, Mancini J, Romera MH, Motte A, Tamalet C, Colson P. Epidemiological, clinical, virological features of hepatitis B newly diagnosed in 2011 in Marseille University hospitals, southeastern France. J Med Virol 2016;88:828-36. [PMID: 26439319 DOI: 10.1002/jmv.24398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Maimone S, Caccamo G, Squadrito G, Alibrandi A, Saffioti F, Spinella R, Raffa G, Pollicino T, Raimondo G. A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. Liver Int 2017;37:362-8. [DOI: 10.1111/liv.13246] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
119 Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, Yuen MF. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014;20:1173-1180. [PMID: 24975365 DOI: 10.1111/1469-0691.12739] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
120 Mohamadkhani A, Bastani F, Khorrami S, Ghanbari R, Eghtesad S, Sharafkhah M, Montazeri G, Poustchi H. Negative Association of Plasma Levels of Vitamin D and miR-378 With Viral Load in Patients With Chronic Hepatitis B Infection. Hepat Mon. 2015;15:e28315. [PMID: 26288634 DOI: 10.5812/hepatmon.28315v2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
121 Liu TW, Yeh ML, Huang CF, Lin IL, Huang JF, Dai CY, Chen YL, Chuang WL, Yu ML. Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. Kaohsiung J Med Sci. 2015;31:26-33. [PMID: 25600917 DOI: 10.1016/j.kjms.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
122 Ahn JM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS One 2015;10:e0144777. [PMID: 26696302 DOI: 10.1371/journal.pone.0144777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
123 Xie Y, Yi W, Zhang L, Lu Y, Hao HX, Gao YJ, Ran CP, Lu HH, Chen QQ, Shen G, Wu SL, Chang M, Ping-Hu L, Liu RY, Sun L, Wan G, Li MH. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J Viral Hepat 2019;26 Suppl 1:42-9. [PMID: 31380591 DOI: 10.1111/jvh.13163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
124 Sun KX, Li J, Zhu FC, Liu JX, Li RC, Zhai XJ, Li YP, Chang ZJ, Nie JJ, Zhuang H. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. Vaccine. 2012;30:5335-5340. [PMID: 22749833 DOI: 10.1016/j.vaccine.2012.06.036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
125 Hu H, Liu J, Chang C, Jen C, Lee M, Lu S, Wang L, Quan Y, Xia N, Chen C, Chen P, Yang H. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. Clinical Gastroenterology and Hepatology 2019;17:172-181.e1. [DOI: 10.1016/j.cgh.2018.04.064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
126 Coffin CS, Terrault NA. Treatment of HCV, HDV, or HIV Coinfection. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 239-62. [DOI: 10.1007/978-981-10-4843-2_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2058] [Article Influence: 240.8] [Reference Citation Analysis]
128 Zannella A, Marignani M, Begini P. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019;11:E858. [PMID: 31540124 DOI: 10.3390/v11090858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Bonacci M, Lens S, Mariño Z, Londoño MC, Rodríguez-Tajes S, Mas A, García-López M, Pérez-Del-Pulgar S, Sánchez-Tapias JM, Forns X. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther 2018;47:1397-408. [PMID: 29577350 DOI: 10.1111/apt.14613] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
130 Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Digestive and Liver Disease 2011;43:S8-S14. [DOI: 10.1016/s1590-8658(10)60686-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
131 Dai CY, Tseng TC, Wong GL, Huang JF, Wong VW, Liu CJ, Yu ML, Chuang WL, Kao JH, Chan HL, Chen DS. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68:2332-2338. [PMID: 23798667 DOI: 10.1093/jac/dkt193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
132 Hong T, Yang H, Kao J. Role of HBsAg Testing in the Management of Patients with Chronic HBV. Curr Hepatology Rep 2019;18:331-41. [DOI: 10.1007/s11901-019-00484-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients: Non-inferiority of TDF to ETV in CHB. Hepatol Res 2018;48:59-68. [DOI: 10.1111/hepr.12902] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
134 Jia W, Song LW, Fang YQ, Wu XF, Liu DY, Xu C, Wang XM, Wang W, Lv DX, Li J, Deng YQ, Wang Y, Huo N, Yu M, Xi HL, Liu D, Zhou YX, Wang GQ, Xia NS, Zhang MX. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) 2014;93:e322. [PMID: 25546679 DOI: 10.1097/MD.0000000000000322] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
135 Sonneveld MJ, Zoutendijk R, Janssen HLA. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. Journal of Viral Hepatitis 2011;18:449-57. [DOI: 10.1111/j.1365-2893.2011.01465.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
136 Cavallone D, Ricco G, Oliveri F, Colombatto P, Moriconi F, Coco B, Romagnoli V, Salvati A, Surace L, Bonino F, Brunetto MR. Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection? Aliment Pharmacol Ther 2020;51:1406-16. [PMID: 32390175 DOI: 10.1111/apt.15753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
137 Colombatto P, Barbera C, Bortolotti F, Maina AM, Moriconi F, Cavallone D, Calvo P, Oliveri F, Bonino F, Brunetto MR. HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. J Med Virol 2018;90:1232-9. [PMID: 29488227 DOI: 10.1002/jmv.25068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
138 Huang DQ, Kew GS, Lim SG. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer. Clin Liver Dis 2021;25:763-84. [PMID: 34593152 DOI: 10.1016/j.cld.2021.06.005] [Reference Citation Analysis]
139 Yuan Q, Song LW, Cavallone D, Moriconi F, Cherubini B, Colombatto P, Oliveri F, Coco BA, Ricco G, Bonino F, Shih JW, Xia NS, Brunetto MR. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. PLoS One 2015;10:e0130209. [PMID: 26115521 DOI: 10.1371/journal.pone.0130209] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
140 Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. Hepatology. 2016;64:381-389. [PMID: 27079545 DOI: 10.1002/hep.28552] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 14.2] [Reference Citation Analysis]
141 Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923-931. [PMID: 23468172 DOI: 10.1002/hep.26376] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
142 Castelain S, Descamps V, Brochot E, Helle F, Duverlie G, Nguyen-Khac E, François C. High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients. Arch Virol 2017;162:1913-20. [PMID: 28289975 DOI: 10.1007/s00705-017-3312-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Ahmed FA, Bajaifar MS, Ahmed MA, Alalwan A, Sanai FA, Albeladi K, Aljumah AA, Sanai FM. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients. Saudi J Gastroenterol 2019;25:286-92. [PMID: 31044750 DOI: 10.4103/sjg.SJG_80_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
144 Romero M, Madejón A, García-samaniego J. ¿Es útil la cuantificación de los niveles del HBsAg en el control del paciente con infección crónica por el virus de la hepatitisB? Gastroenterología y Hepatología 2014;37:350-3. [DOI: 10.1016/j.gastrohep.2013.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013;48:13-21. [PMID: 23090000 DOI: 10.1007/s00535-012-0668-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
146 Wang C, Pan YC, Jia ZF, Chi XM, Wang YQ, Yang N, Wu YH, Niu JQ, Jiang J. The relationship between hepatitis B virus serum DNA, RNA and quantitative hepatitis B surface antigen, and the predictive value for mother-to-child transmission: an observational cohort study. BJOG 2021. [PMID: 34455680 DOI: 10.1111/1471-0528.16884] [Reference Citation Analysis]
147 Su TH, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen CL, Chen PJ, Kao JH, Chen DS. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One. 2013;8:e55916. [PMID: 23437072 DOI: 10.1371/journal.pone.0055916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
148 Loggi E, Vukotic R, Conti F, Grandini E, Gitto S, Cursaro C, Galli S, Furlini G, Re MC, Andreone P. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:568-75. [PMID: 30576048 DOI: 10.1111/jvh.13054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
149 Wang H, Yan R, Zhou Y, Wang MS, Ruo GQ, Cheng MJ. Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients. Hepatol Int 2014;8:216-23. [DOI: 10.1007/s12072-013-9502-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
150 Höner Zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice? J Viral Hepat 2018;25:1226-35. [PMID: 30187603 DOI: 10.1111/jvh.12993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
151 Brouwer WP, van der Meer AJP, Boonstra A, Plompen EPC, Pas SD, de Knegt RJ, de Man RA, Ten Kate FJW, Janssen HLA, Hansen BE. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat. 2017;24:1023-1031. [PMID: 28544398 DOI: 10.1111/jvh.12727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
152 Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, Taranta A, Manns MP, Wedemeyer H, Glebe D, Cornberg M. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1-10. [PMID: 25700889 DOI: 10.1016/j.cmi.2015.02.010] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 10.2] [Reference Citation Analysis]
153 Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother. 2015;59:4121-4128. [PMID: 25941216 DOI: 10.1128/AAC.00249-15] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 6.2] [Reference Citation Analysis]
154 Yıldız Kaya S, Mete B, Kaya A, Balkan II, Saltoglu N, Tabak ÖF. The role of quantitative HBsAg in patients with HBV DNA between 2000-20,000 IU/ml. Wien Klin Wochenschr 2021;133:647-53. [PMID: 33914152 DOI: 10.1007/s00508-021-01854-7] [Reference Citation Analysis]
155 Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu CJ, Li Y, Manns MP, Lengauer T, Wedemeyer H, Kraft ARM, Falk CS, Cornberg M. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci Rep 2019;9:14118. [PMID: 31575964 DOI: 10.1038/s41598-019-50729-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 2018;67:2045-53. [PMID: 28951526 DOI: 10.1136/gutjnl-2017-313811] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
157 de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. The Lancet Gastroenterology & Hepatology 2017;2:576-84. [DOI: 10.1016/s2468-1253(17)30083-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
158 Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso AC, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol. 2013;58:1089-1095. [PMID: 23369792 DOI: 10.1016/j.jhep.2013.01.028] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 9.6] [Reference Citation Analysis]
159 Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. Int J Environ Res Public Health 2019;16:E3307. [PMID: 31505743 DOI: 10.3390/ijerph16183307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
160 Guner R, Karahocagil M, Buyukberber M, Kandemir O, Ural O, Usluer G, Inan D, Koksal I, Baykam N, Hizel K, Yamazhan T, Esen S, Tasyaran MA. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol 2011;23:1185-91. [PMID: 21934508 DOI: 10.1097/MEG.0b013e32834ba13a] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
161 Zhou K, Wahed AS, Cooper S, Di Bisceglie AM, Fontana RJ, Ghany MG, Khalili M, Lok AS, Perrillo R, Lee WM, Lau DTY, Sterling R, Janssen HLA, Terrault NA. Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. Am J Gastroenterol 2019;114:1753-63. [PMID: 31658127 DOI: 10.14309/ajg.0000000000000400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
162 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
163 Delle Monache M, Petrelli A, Rossi A, Cecere R, Mirisola C, Costanzo G, Francia C, Cerini F, Cavani A, Nosotti L. Noninvasive Evaluation of Liver Fibrosis in a Sample of Putative Inactive HBV Carriers in Rome, Italy. Can J Infect Dis Med Microbiol 2021;2021:3068690. [PMID: 34426755 DOI: 10.1155/2021/3068690] [Reference Citation Analysis]
164 Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int. 2013;33 Suppl 1:125-132. [PMID: 23286856 DOI: 10.1111/liv.12075] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
165 Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622. [PMID: 24787673 DOI: 10.1586/17474124.2014.909724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
166 Morita S, Matsumoto A, Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Yoshizawa K, Tanaka E. Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B: Characteristics of HBeAg negative hepatitis. Hepatol Res 2014;44:E45-53. [DOI: 10.1111/hepr.12208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
167 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Hsu CA, Kuo SF, Liu CH, Chen PJ. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441-450. [PMID: 22941922 DOI: 10.1002/hep.26041] [Cited by in Crossref: 161] [Cited by in F6Publishing: 159] [Article Influence: 17.9] [Reference Citation Analysis]
168 Burdino E, Ruggiero T, Proietti A, Milia MG, Olivero A, Caviglia GP, Marietti M, Rizzetto M, Smedile A, Ghisetti V. Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. Journal of Clinical Virology 2014;60:341-6. [DOI: 10.1016/j.jcv.2014.05.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
169 Ghany MG, King WC, Lisker-Melman M, Lok ASF, Terrault N, Janssen HLA, Khalili M, Chung RT, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology 2021. [PMID: 34133774 DOI: 10.1002/hep.32018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 谭雷, 吴泽倩, 刘婷, 高志良, 柯伟民. HBeAg阳性慢性乙型肝炎不同肝组织炎症与纤维化时期血清HBsAg含量的动力学特点. 世界华人消化杂志 2014; 22(14): 2023-2027 [DOI: 10.11569/wcjd.v22.i14.2023] [Reference Citation Analysis]
171 Lin CL, Kao JH. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:423-431. [PMID: 28081591 DOI: 10.3350/cmh.2016.0069] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
172 Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2012;10:297-302. [PMID: 21893131 DOI: 10.1016/j.cgh.2011.08.029] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
173 Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Practice & Research Clinical Gastroenterology 2017;31:281-9. [DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
174 Su T, Kao J. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:141-54. [DOI: 10.1586/17474124.2015.960398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
175 Świderska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Płońska M, Stawicka A, Panasiuk A, Flisiak R. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm 2017;2017:3480234. [PMID: 28827897 DOI: 10.1155/2017/3480234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
176 Xun YH, Zang GQ, Guo JC, Yu XL, Liu H, Xiang J, Liu J, Shi JP. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol. 2013;28:1746-1755. [PMID: 23800140 DOI: 10.1111/jgh.12304] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
177 Cox NR, Patel K, Tillmann HL. A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B. Mol Diagn Ther 2014;18:203-12. [DOI: 10.1007/s40291-013-0072-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
178 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
179 Taida T, Arai M, Kanda T, Hige S, Ueno Y, Imazeki F, Izumi N, Tanaka E, Shinkai N, Yoshioka K, Nakamoto Y, Nishiguchi S, Tsuge M, Abe M, Sata M, Yatsuhashi H, Ido A, Kita K, Azemoto R, Kitsukawa Y, Goto N, Yokosuka O. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. J Gastroenterol 2017;52:113-22. [PMID: 27306374 DOI: 10.1007/s00535-016-1229-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
180 Yu Y, Hou J, Omata M, Wang Y, Li L. Loss of HBsAg and antiviral treatment: from basics to clinical significance. Hepatol Int 2014;8:39-54. [PMID: 26202405 DOI: 10.1007/s12072-013-9495-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
181 Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 9.1] [Reference Citation Analysis]
182 Peiffer KH, Spengler C, Basic M, Jiang B, Kuhnhenn L, Obermann W, Zahn T, Glitscher M, Loglio A, Facchetti F, Carra G, Kubesch A, Vermehren J, Knop V, Graf C, Dietz J, Finkelmeier F, Herrmann E, Trebicka J, Grünweller A, Zeuzem S, Sarrazin C, Lampertico P, Hildt E. Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight 2020;5:135833. [PMID: 33055418 DOI: 10.1172/jci.insight.135833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Chan HL. Identifying hepatitis B carriers at low risk for hepatocellular carcinoma. Gastroenterology 2012;142:1057-60. [PMID: 22449578 DOI: 10.1053/j.gastro.2012.03.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
184 Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
185 Wong GL, Wong VW, Chan HL. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis 2016;62 Suppl 4:S298-305. [PMID: 27190319 DOI: 10.1093/cid/ciw024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
186 Liu J, Tseng T, Yang H, Lee M, Batrla-utermann R, Jen C, Lu S, Wang L, You S, Chen P, Chen C, Kao J. Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. Journal of Infectious Diseases 2015;211:1566-73. [DOI: 10.1093/infdis/jiu659] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
187 Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology. 2011;53:2121-2129. [PMID: 21503943 DOI: 10.1002/hep.24364] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
188 Brouwer WP, Chan HL, Brunetto MR, Martinot-Peignoux M, Arends P, Cornberg M, Cherubini B, Thompson AJ, Liaw YF, Marcellin P, Janssen HL, Hansen BE; Good Practice in using HBsAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group). Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. Clin Gastroenterol Hepatol. 2016;14:1481-1489.e5. [PMID: 26872398 DOI: 10.1016/j.cgh.2016.01.019] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
189 Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K. High Levels of Hepatitis B Virus After the Onset of Disease Lead to Chronic Infection in Patients With Acute Hepatitis B. Clinical Infectious Diseases 2013;57:935-42. [DOI: 10.1093/cid/cit348] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
190 Li MH, Xie Y, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Hu LP, Hua WH, Song SJ, Zhang SF, Cheng J, Xu DZ. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol 2016; 8(15): 637-643 [PMID: 27239256 DOI: 10.4254/wjh.v8.i15.637] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
191 Ayoub WS, Cohen E. Hepatitis B Management in the Pregnant Patient: An Update. J Clin Transl Hepatol 2016;4:241-7. [PMID: 27777892 DOI: 10.14218/JCTH.2016.00014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
192 Loggi E, Bihl FK, Cursaro C, Granieri C, Galli S, Brodosi L, Furlini G, Bernardi M, Brander C, Andreone P. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One. 2013;8:e65327. [PMID: 23750252 DOI: 10.1371/journal.pone.0065327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
193 Pivert A, Servant-Delmas A, Lunel-Fabiani F, Le Guillou-Guillemette H, Laperche S, Ducancelle A. Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus. J Med Virol 2015;87:529-35. [PMID: 25170961 DOI: 10.1002/jmv.24064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
194 Karajibani M, Hasanjani Roushan MR, Bayani M, Javanian M, Masrour-Roudsari J. Spontaneous relapse in patients with inactive chronic hepatitis B virus infection. Caspian J Intern Med 2018;9:393-6. [PMID: 30510655 DOI: 10.22088/cjim.9.4.393] [Reference Citation Analysis]
195 Pita I, Horta-vale AM, Cardoso H, Macedo G. Hepatitis B inactive carriers: An overlooked population? GE Portuguese Journal of Gastroenterology 2014;21:241-9. [DOI: 10.1016/j.jpge.2014.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
196 Popalis C, Yeung LT, Ling SC, Ng V, Roberts EA. Chronic hepatitis B virus (HBV) infection in children: 25 years’ experience. J Viral Hepat. 2013;20:e20-e26. [PMID: 23490385 DOI: 10.1111/jvh.12019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
197 Chevaliez S. Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol. 2013;37:559-563. [PMID: 23932705 DOI: 10.1016/j.clinre.2013.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
198 Guardiola-Arévalo A, Gómez Rodríguez R, Romero Gutiérrez M, Gómez Moreno AZ, García Vela A, Sánchez Simón R, Gómez Hernando C, Andrés Esteban EM. Hepatitis B virus e antigen-negative chronic infection. Treatment based on glutamic pyruvic transaminase and hepatitis B virus deoxyribonucleic acid cut-off values. Gastroenterol Hepatol 2018;41:153-62. [PMID: 29279233 DOI: 10.1016/j.gastrohep.2017.11.003] [Reference Citation Analysis]
199 Mcmahon BJ. Hepatitis B Surface Antigen (HBsAg): A 40-Year-Old Hepatitis B Virus Seromarker Gets New Life. Gastroenterology 2010;139:380-2. [DOI: 10.1053/j.gastro.2010.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
200 Yang Y, Gao J, Tan YT, Li HL, Wang J, Ma X, Zheng W, Shu XO, Xiang YB. Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. J Gastroenterol Hepatol 2018;33:1131-7. [PMID: 29065440 DOI: 10.1111/jgh.14032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
201 Tan Z, Li M, Kuang X, Tang Y, Fan Y, Deng G, Wang Y, He D. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. Journal of Clinical Virology 2014;59:228-34. [DOI: 10.1016/j.jcv.2014.01.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
202 Balkan A, Namiduru M, Balkan Y, Mete AO, Karaoglan I, Bosnak VK. Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients? Saudi J Gastroenterol 2016;22:208-14. [PMID: 27184639 DOI: 10.4103/1319-3767.182454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
203 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-1149.e3; quiz e13-14. [PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007] [Cited by in Crossref: 307] [Cited by in F6Publishing: 295] [Article Influence: 34.1] [Reference Citation Analysis]
204 Wu ZQ, Tan L, Liu T, Gao ZL, Ke WM. Evaluation of changes of serum hepatitis B surface antigen from a different perspective. World J Gastroenterol 2015; 21(9): 2739-2745 [PMID: 25759544 DOI: 10.3748/wjg.v21.i9.2739] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
205 Buti M, Rodríguez Frías F, Esteban R. Cuantificación del antígeno de superficie del virus de la hepatitis B: implicaciones clínicas. Medicina Clínica 2012;138:483-8. [DOI: 10.1016/j.medcli.2011.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Cheng XD, Song LW, Fang LL, Yang L, Wu Y, Ge SX, Yuan Q, Zhang J, Xia NS, Hao XK. Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection. Clin Vaccine Immunol 2014;21:1521-7. [PMID: 25209557 DOI: 10.1128/CVI.00529-14] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
207 Chakrabarty G, Bruce M, Horner M, Wang B, Agarwal K, Carey I. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients? J Viral Hepat 2018;25:80-7. [PMID: 28710798 DOI: 10.1111/jvh.12756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
208 Riveiro-Barciela M, Bes M, Rodríguez-Frías F, Tabernero D, Ruiz A, Casillas R, Vidal-González J, Homs M, Nieto L, Sauleda S, Esteban R, Buti M. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. Clin Microbiol Infect 2017;23:860-7. [PMID: 28288829 DOI: 10.1016/j.cmi.2017.03.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
209 Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013;59:709-716. [PMID: 23792029 DOI: 10.1016/j.jhep.2013.06.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
210 Gu Y, Lian Y, Zheng Q, Huang Z, Gu L, Bi Y, Li J, Huang Y, Wu Y, Chen L, Huang Y. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B. BMC Infect Dis 2020;20:509. [PMID: 32664850 DOI: 10.1186/s12879-020-05233-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim DY, Han K, Chon CY, Park JY. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int 2012;32:796-802. [DOI: 10.1111/j.1478-3231.2011.02693.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
212 Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol 2011; 3(12): 292-299 [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
213 Ramachandran J, Ismail AM, Chawla G, Fletcher GJ, Goel A, Eapen CE, Abraham P. Serum HBsAg quantification in treatment-naïve Indian patients with chronic hepatitis B. Indian J Gastroenterol. 2014;33:131-135. [PMID: 24052375 DOI: 10.1007/s12664-013-0395-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
214 Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fang YJ, Hung HW, Wu CY, Lin JT. Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients. Clin Gastroenterol Hepatol 2016;14:1490-1498.e3. [PMID: 27018299 DOI: 10.1016/j.cgh.2016.03.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
215 Liu L, Liu C, Li J, Du Y, Chen J, Wang H, Li H, Chang L. Analysis of pathological changes and related factors in liver tissue of HBeAg-negative patients with low HBsAg levels. Clin Exp Med 2020;20:577-86. [PMID: 32656675 DOI: 10.1007/s10238-020-00645-0] [Reference Citation Analysis]
216 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
217 Oliveri F, Surace L, Cavallone D, Colombatto P, Ricco G, Salvati N, Coco B, Romagnoli V, Gattai R, Salvati A. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance. Liver Int. 2017;37:1622-1631. [PMID: 28296013 DOI: 10.1111/liv.13416] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
218 Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, La Rosa KY, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, T Kennedy P, Verheyen J, Aquaro S, Silberstein FC, Perno CF, Svicher V. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerg Microbes Infect 2020;9:928-39. [PMID: 32312174 DOI: 10.1080/22221751.2020.1757998] [Reference Citation Analysis]
219 McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54. [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
220 Yu F, Yang J, Ouyang J, Zheng Y, Chen B, Li G, Lu Z, Dong P, Zheng J. Serum microRNA-210 levels in different groups of chronic hepatitis B patients. Clinica Chimica Acta 2015;450:203-9. [DOI: 10.1016/j.cca.2015.08.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
221 Baklouti R, Gueddiche A, Ben Abdelwahed M, Aissaoui F, Zakhama M, Bouhlel W, Sriha A, Kooli I, Sallem OK, Argoubi A, Hichem LM, Ben Chaabane N, Safer L. The role of quantitative HBsAg in the natural history of e antigen-negative chronic hepatitis B: A Tunisian prospective study. Infect Dis Now 2021;51:464-9. [PMID: 34366082 DOI: 10.1016/j.idnow.2020.10.004] [Reference Citation Analysis]
222 Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011;35:813-8. [PMID: 21821479 DOI: 10.1016/j.clinre.2011.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
223 Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, Liu RY, Hu LP, Cao WH, Chen QQ, Li JN, Wan G, Xie Y. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat 2019;26 Suppl 1:32-41. [PMID: 31380582 DOI: 10.1111/jvh.13151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
224 Gupta E, Pandey P, Kumar A, Sharma MK, Sarin SK. Correlation between two chemiluminescence based assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B infection. Indian J Med Microbiol. 2015;33:96-100. [PMID: 25560010 DOI: 10.4103/0255-0857.148400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
225 Kawanaka M, Nishino K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G. Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. Liver Cancer. 2014;3:41-52. [PMID: 24804176 DOI: 10.1159/000343857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
226 Mukherjee RM, Shravanti GV, Jakkampudi A, Kota R, Jangala AL, Reddy PB, Rao PN, Gupta R, Reddy DN. Reduced Expression of DNA Damage Repair Genes High Mobility Group Box1 and Poly(ADP-ribose) Polymerase1 in Inactive Carriers of Hepatitis B Virus Infection-A Possible Stage of Viral Integration. J Clin Exp Hepatol 2013;3:89-95. [PMID: 25755481 DOI: 10.1016/j.jceh.2013.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
227 Su TH, Liu CJ. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver 2017;11:590-603. [PMID: 28494575 DOI: 10.5009/gnl16215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
228 Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58:853-860. [PMID: 23246508 DOI: 10.1016/j.jhep.2012.12.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
229 Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436. [PMID: 25934462 DOI: 10.1101/cshperspect.a021436] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 18.3] [Reference Citation Analysis]
230 Karayiannis P. Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment. Hepat Mon. 2012;12:420-422. [PMID: 23008721 DOI: 10.5812/hepatmon.6201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
231 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
232 Hadziyannis E, Hadziyannis SJ. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. Expert Review of Gastroenterology & Hepatology 2013;8:185-95. [DOI: 10.1586/17474124.2014.876362] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
233 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
234 De Paschale M, Manco MT, Belvisi L, Cagnin D, Cerulli T, Paganini A, Arpino O, Cianflone A, Agrappi C, Mirri P, Clerici P. Evaluation of LIAISON® XL system for HBsAg, and anti-HCV and anti-HIV/Ag p24. J Med Virol 2017;89:489-96. [PMID: 27467710 DOI: 10.1002/jmv.24648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]